Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00245648
: October 28, 2005
Last Update Posted
: October 4, 2012
New York University School of Medicine
The Cleveland Clinic
Eli Lilly and Company
Information provided by (Responsible Party):
Harmony R. Reynolds, New York University School of Medicine
This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.
Condition or disease
Drug: fibrinolytic therapy or combination reduced fibrinolytic therapy
The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO) V trial examined a large, contemporary cohort of women and men with ST elevation myocardial infarction (STEMI) treated with fibrinolytic therapy. The objective of the present study was to evaluate sex differences in presentation, management and outcome in GUSTO V.
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
All cause mortality at 30 days after randomization.
Secondary Outcome Measures
Secondary Outcomes [ Time Frame: 7 days ]
Incidence of myocardial reinfarction as evidenced by new electrocardiographic changes or elevation in cardiac enzyme levels with recurrent chest pain within 7 days, bleeding, stoke, intracranial hemorrhage (ICH), and complications of MI.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.